Emerging Markets
The latest news, updates and opinions on Emerging Markets from the expert team here at MoneyWeek
-
Mark Mobius – the “Indiana Jones of investing” who died aged 89Mark Mobius was an intrepid emerging-markets investor who made many winning bets in the heat of crises. He will be sorely missed
By Jane Lewis Published
-
Does instability in the US mean a bright future for Brazil?Brazil could be a good place to start for investors looking for long-term winners and losers as the US upends the world order
By Cris Sholto Heaton Published
-
How to invest in Asian markets – no longer just ‘emerging’Asian markets account for the majority of the emerging markets index, and many of the largest companies are highly advanced, says Max King
By Max King Published
-
The best funds to buy as Vietnam evolvesVietnam may get promoted to emerging-market status, drawing more foreign investors. Here, Rupert Hargreaves picks three of the best Vietnam-focused funds to buy
By Rupert Hargreaves Published
-
Why Vietnam is the world's most exciting emerging market: MoneyWeek TalksPodcast Dominic Scriven, founder of asset manager Dragon Capital, speaks to Cris Sholto Heaton about the challenges and opportunities that lie ahead for Vietnam.
By Cris Sholto Heaton Published
Podcast -
Stock market circuit breaker: Why did Korean shares pause trading?The fallout from the conflict in the Middle East hit the Korean stock market on 4 March, with shares forced to temporarily stop trading. What is a stock market circuit breaker, and why did the KOSPI trigger one?
By Dan McEvoy Published
-
Why do experts think emerging markets will outperform?Emerging markets were one of the top-performing themes of 2025, but they could have further to run as global investors diversify
By Dan McEvoy Published
-
Three emerging-market stocks to diversify your portfolioOpinion Omar Negyal, portfolio manager, JPMorgan Global Emerging Markets Income Trust, highlights three emerging-market stocks where he’d put his money
By Omar Negyal Published
Opinion -
Exciting opportunities in biotechBiotech firms should profit from the ‘patent cliff’, which will force big pharmaceutical companies to innovate or make acquisitions
By Max King Published
